Patents by Inventor Mary J. Tanga

Mary J. Tanga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)-KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN
    Publication number: 20200360393
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine , or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-Hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 19, 2020
    Inventors: IRVING W. WAINER, RUIN MOADDEL, MICHEL BERNIER, CARLOS A. ZARATE, MARC C. TORJMAN, MICHAEL E. GOLDBERG, MARY J. TANGA
  • USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN
    Publication number: 20180098993
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 12, 2018
    Inventors: IRVING W. WAINER, RUIN MOADDEL, MICHEL BERNIER, CARLOS A. ZARATE, MARC C. TORJMAN, MICHAEL E. GOLDBERG, MARY J. TANGA
  • Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
    Patent number: 9867830
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 16, 2018
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, COOPER HEALTH SYSTEM, SRI INTERNATIONAL
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
    Patent number: 9650352
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 16, 2017
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, COOPER HEALTH SYSTEM, SRI INTERNATIONAL
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN
    Publication number: 20170049780
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 23, 2017
    Inventors: IRVING W. WAINER, RUIN MOADDEL, MICHEL BERNIER, CARLOS A. ZARATE, MARC C. TORJMAN, MICHAEL E. GOLDBERG, MARY J. TANGA
  • THE USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN
    Publication number: 20140296241
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Arsenical Fluorescent Agents and Assays
    Publication number: 20140162309
    Abstract: The invention provides methods and compositions for labeling dithiol-containing analytes, including a substituted, optionally hydro-, optionally hetero-, monoarsenical anthracene compound comprising a 4? rotation blocking group and a 5? arsenic, and that exhibits a detectable increase or shift in fluorescence when the arsenic reacts with two thiols of a rotation-blocking binding target molecule.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: SRI INTERNATIONAL
    Inventors: Laura Ellen Downs Beaulieu, Mary J. Tanga
  • Arsenical fluorescent agents and assays
    Patent number: 8664009
    Abstract: The invention provides methods and compositions for labeling dithiol-containing analytes.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: March 4, 2014
    Assignee: SRI International
    Inventors: Laura Ellen Downs Beaulieu, Mary J. Tanga
  • Compounds for activating TGF-beta signaling
    Patent number: 8410138
    Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-? signaling are described.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: April 2, 2013
    Assignees: The Board of Trustees of the Leland Stanford Junior University, SRI International
    Inventors: Anton Wyss-Coray, Mary J. Tanga
  • COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING
    Publication number: 20120095000
    Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-? signaling are described.
    Type: Application
    Filed: December 12, 2011
    Publication date: April 19, 2012
    Applicants: SRI International, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Anton Wyss-Coray, Mary J. Tanga
  • Compounds for activating TGF-? signaling
    Patent number: 8097645
    Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-? signaling are described.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: January 17, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, SRI International
    Inventors: Anton Wyss-Coray, Mary J. Tanga
  • Arsenical Fluorescent Agents and Assays
    Publication number: 20110229929
    Abstract: The invention provides methods and compositions for labeling dithiol-containing analytes.
    Type: Application
    Filed: March 21, 2011
    Publication date: September 22, 2011
    Inventors: Laura Ellen Downs Beaulieu, Mary J. Tanga
  • COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING
    Publication number: 20090143394
    Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-? signaling are described.
    Type: Application
    Filed: October 10, 2008
    Publication date: June 4, 2009
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Anton Wyss-Coray, Mary J. Tanga